(精选)Oncology Grand Rounds Lymphomas and Chronic Lymphocytic Leukemia教学课件.pptVIP

下载本文档

0
0
约5.78千字
约 81页
2018-03-21 发布于天津
举报
版权申诉

(精选)Oncology Grand Rounds Lymphomas and Chronic Lymphocytic Leukemia教学课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

演示文稿演讲PPT学习教学课件医学文件教学培训课件

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. ;ModeratorNeil Love, MD;Oncology Grand Rounds Series;Oncology Grand Rounds: Themes;Discussion Topics;54-Year-Old Man with CLL (Ms Goodrich);54-Year-Old Man with CLL (Ms Goodrich);54-Year-Old Man with CLL (Ms Goodrich);Oncologic Rationale for Treatment Selection: Front-Line Treatment Options;Cytogenetics of CLL and Prognosis;Mechanism of action: A humanized, glycoengineered CD20 monoclonal antibody that enhances antibody-dependent, cell-mediated cytotoxicity Indication in CLL: In combination with chlorambucil for the treatment of previously untreated CLL Recommended dose for CLL: 100 mg IV on day 1 and 900 mg IV on day 2 of cycle 1 1,000 mg IV on days 8 and 15 of cycle 1 and 1,000 mg IV on day 1 of cycles 2-6. ;Comparison of cell death induced byobinutuzumab and rituximab;Chlorambucil + obinutuzumab (G-Clb);Mechanism of action: An oral, selective inhibitor of Bruton tyrosine kinase activity Indication in CLL: For the treatment of CLL in patients who carry a del(17p) mutation For patients with CLL who have received at least 1 prior therapy For patients with treatment-na?ve CLL Recommended dose for CLL: 420 mg orally once daily;;RESONATE-2: PFS with Ibrutinib in Patients with Untreated CLL Aged ≥65 Years;RESONATE-2: Select Ibrutinib-Associated Adverse Events (AEs);Case discussion points (Ms Goodrich);75-Year-Old Man with CLL (Ms Stephans);75-Year-Old Man with CLL (Ms Stephans);Mechanism of action: An orally available Bcl-2 inhibitor Indication: For the treatment of CLL in patients who carry a del(17p) mutation and who have received at least 1 prior therapy Recommended dose: 20 mg orally once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended dose of 400 mg. Administer with food;Mechanism of Action of Venetoclax (ABT-199);Stilgenbauer S et al. Proc ASH 2015;Abstract LBA-6.;On Apri